Friday, March 04, 2016

The art of drawing: Sir Peter Cook completes first ever building in the UK

ARCHITECTURE / / BY ELLIE STATHAKI

Sir Peter Cook and his office CRAB (Cook Robotham Architectural Bureau) have just completed the drawing studio at the Arts University Bournemouth - the first of its kind to be built in the UK in 100 years
___________________________________________
Celebrating the art of drawing – and teaching – the Arts University Bournemouth has just launched its brand new drawing studio, the first of its kind to be built in the UK in 100 years. 
The striking blue structure features the playful, organic-shaped volumes that form the signature of its creator; AUB alumnus and renowned architect and academic Sir Peter Cook and his office CRAB (Cook Robotham Architectural Bureau). 
The structure, purpose-built for the art school, will be accessible to students from all courses across the University. Its clean white and generous interior is flexible enough to be able to accommodate work by several different disciplines - from costume design, to architecture, animation and etching. 
Special attention was given to the room's openings and the direction of natural sunlight. A large north-facing opening on the roof brings in the type of light that is traditionally optimum for drawing. At the same time, a rear clerestory window tops up with softer light from the back. 
'As an alumnus of AUB, I am deeply honoured that this University, where I learnt my craft, is now home to my first building in the UK,' says Cook. 'The studio represents a fundamental recognition of the importance of drawing for all creative subjects. When it came to the design of the studio I wanted to ensure I created a space which all students, from all disciplines – be it fashion design, graphic design, fine art, or architecture like me – could make use of and feel inspired in.'
Highlighting the project's importance, Dame Zaha Hadid is set to attend the official opening today. This inauguration also marks Sir Peter Cook's very first built work in the UK.

Read more at http://www.wallpaper.com/architecture/the-art-of-drawing-sir-peter-cook-completes-first-even-building-in-the-uk#Sd6CFvrbMGCJGR77.99

Sun Pharma looking to leverage Ranbaxy OTC drugs: Dilip Shanghvi

India’s largest drugmaker Sun Pharmaceutical is looking to leverage the over-the-counter (OTC)  drugs’ portfolio of Ranbaxy Laboratories, which it acquired two year, to expand its global presence.
Sun Pharma had no presence in the high-volumes OTC segment — medicines sold directly to a consumer without prescription — before the acquisition of Ranbaxy. It recently rolled out its first OTC  drug, antacid Pepmelt, that will compete with Eno, Digene and Pudin Hara.
“Our consumer healthcare, or OTC business is a result of acquisition of Ranbaxy. It is a high-margin, high-growth business. We want to use this as a base to create a global OTC business,” Dilip Shanghvi, managing director, Sun Pharma told HT. “So, we are actually giving lot of internal focus and importance to it.”
When Sun Pharma acquired Ranbaxy, consumer healthcare was the latter’s fastest-growing businesses, with leading brands such as Revital, Volini, Chericof, Pepfiz and Garlic Pearls. Ranbaxy has 15 OTC products, which contributed over 20% of Ranbaxy’s sales before acquisition.
“The two top-growing segments in OTC are health supplements and analgesics and we are witnessing growth healthier than growth rate of the entire OTC market,” said Subodh Marwah, vice-president — consumer healthcare business, Sun Pharma. “So we are actually giving lot of internal focus and importance on growing that part of the business.”
“Consumer health business is important for our future growth not only in India but in other markets where we have presence, where our idea is to grow the business and look at potential inorganic opportunities,” Shanghvi said.
According to market analysts, OTC medicines contribute 10% to 15% to Sun Pharma’s revenues. Brands such Revital (health supplement) and Volini (analgesic) feature among top 10 brands of the country and Sun Pharma is likely to make significant investment in these categories.
As per Neilsen estimates, the antacids category is currently pegged at over Rs 1,180 crore, growing at around 21% every year. The total OTC market in India is pegged at around Rs 5,300 crore, growing annually at around 12% to 13%.

Eli Lilly launches once-a-week diabetes drug in India

"India is the third country after Japan and the UAE in Asia and it (Trulicity) is already available in the US and Europe. This complements our diabetes portfolio in India," Olaizola said. 

In a move to enhance its diabetes portfolio in India, US pharma major Eli Lilly has launched once-a-week diabetes treatment drug under the brand name 'Trulicity', at Rs 2,499 in the country. The company has launched the product after receiving the regulatory approval for the same in India. "We are pleased to be introducing Trulicity, first, once-a-week diabetes medicine, in India. We have been committed to diabetes for more than 90 years. We are bringing a new medication to India with a proven efficacy," Eli Lilly India Managing Director Edgard Olaizola told PTI. "The medicine is an injectable medication and belongs to a class called GLP-1 receptor agonists. It is not a insulin," he added. Trulicity comes in a single-dose pen and is designed to improve the blood sugar control in adults with Type 2 diabetes. "India is the third country after Japan and the UAE in Asia and it (Trulicity) is already available in the US and Europe. This complements our diabetes portfolio in India," Olaizola said. For Eli Lilly, diabetes is the biggest segment with "about 85 percent of our sales in India coming from diabetes and we are growing double digit and growing our market share," he added. After diabetes, the other important segment is oncology. The others are osteoporosis and human growth hormone, he added. The company is also looking to introduce another medication in oncology. "We are working to bring an oncology product to India and we are working with regulatory agencies for this," Olaizola said. The company expects to introduce the product by next year, he added. Eli Lilly sells a range of medicines and drug delivery devices in the diabetes segment. In 2014, it had introduced Savvio, an insulin delivery device in India.

Read more at: http://www.moneycontrol.com/news/business/eli-lilly-launches-once-a-week-diabetes-drugindia_5744581.html?utm_source=ref_article

Wednesday, March 02, 2016

Budget 2016: Jaitley announces 3,000 new drug stores, dialysis centres

"For the better availability of generic medicines in the country, especially in the rural areas, the government has decided to open 3,000 new gereric medicines stores," Arun Jaitley said, presenting the Union Budget for 2016-17 in the Lok Sabha.

NEW DELHI: The government will set up 3,000 new generic medicine stores across the country to tackle the shortage of drugs in rural areas, finance minister Arun Jaitley said on Monday.

"For the better availability of generic medicines in the country, especially in the rural areas, the government has decided to open 3,000 new gereric medicines stores," said Jaitley, presenting the Union Budget for 2016-17 in the Lok Sabha.

He also announced the launch of a National Dialysis Programme to address the high costs involved in the renal dialysis processes.

Under the programme every district hospital will have the facilities of renal dialysis, so that people do not have to travel to the expensive hospitals of metro cities, he said.

At least 2,000 new dialysis centres will be started in the country under the programme.
SOURCE: http://retail.economictimes.indiatimes.com/news/health-and-beauty/pharmacy/budget-2016-jaitley-announces-3000-new-drug-stores-dialysis-centres/51203603

QUALITY OF INDIAN DRUGS


P A Francis
Wednesday, March 02, 2016, 08:00 Hrs  [IST]
Indian pharmaceutical industry has been passing through a difficult phase for the last five years with its export prospects getting threatened on account of regulatory actions by the US Food & Drug Administration (US FDA) and European Medical Agency (EMA). Regulatory inspections and actions by these agencies and consequent drop in exports have been hitting the profitability of India’s top large and medium scale pharma companies as their profits mainly come from generic exports to these countries. India supplies more than 30 per cent of the generic medicines sold in the US and nearly 25 per cent sold in the European Union. There has been a steady increase in issuance of warning letters and import alerts by the US FDA and EMA on Indian pharmaceutical manufacturing facilities with regulators’ increasing concern over the safety of drugs imported into their countries. The US FDA alone issued 15 warning letters to Indian pharma companies during 2015. Between 2008 and 2015, US FDA has issued around 50 warning letters on Indian companies and out of these, around 40 per cent were converted into import alerts. India has more than 600 US FDA approved manufacturing facilities located in different parts of the country. Warning letters are issued after regular inspections of the stringent manufacturing standards laid down by these agencies.

Quality issues arising out of regulatory actions by the US FDA and EMA have been an issue of serious discussion among the industry bodies and the concerned government departments for some time. Such repeated actions by the world’s top regulatory authorities not only affect India’s generic exports but also the reputation of India as a global supplier of quality generics at reasonable prices. Indian Pharmaceutical Alliance, a body of 20 large research based Indian pharma companies, has been addressing this issue quite seriously. It recently held a meeting of representatives from US FDA, UK MHRA, Drug Controller General of India and Indian drug exporters. Main complaints from regulators ranged from issues over hygiene and maintenance to concerns over documentation and data management. There is a growing feeling among the regulators that some Indian companies are still not taking enough steps to identify risks and failures at their facilities even after issue of several warning letters. Regulatory officials from the US, EU and UK at the meeting therefore said that they would step up the number of inspections in India, and are expecting better cooperation from the exporting companies and Indian authorities. That is indeed a legitimate expectation and Indian pharma exporters have to take this matter seriously considering the price these countries are offering to Indian products.

SOURCE: http://www.pharmabiz.com/ArticleDetails.aspx?aid=93796&sid=3